Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097

12 May 2015

Abstract excerpt

Biomarkers for patient selection are essential for the successful and rapid development of emerging targeted anti-cancer therapeutics. In this study, we report the discovery of a novel patient selection strategy for the p53-HDM2 inhibitor NVP-CGM097, currently under evaluation in clinical trials. By intersecting high-throughput cell line sensitivity data with genomic data, we have identified a gene expression...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Cancer-related Molecular Pathways
Share to Epigenetics and DNA Methylation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25965177
DOI: 10.7554/elife.06498

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097PMID 25965177Read ↗

A p53 Drug Response Signature Identifies Prognostic Genes in High-Risk NeuroblastomaSemantic proximity Read ↗

Discovery of Potent and Selective p53-MDM2 Protein–Protein Interaction Inhibitors as Anticancer DrugsSemantic proximity Read ↗

Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 InhibitionSemantic proximity Read ↗

Data Mining Approaches for Genomic Biomarker Development: Applications Using Drug Screening Data from the Cancer Genome Project and the Cancer Cell Line Encyclopedia.Semantic proximity Read ↗

Drug Sensitivity Prediction From Cell Line-Based Pharmacogenomics Data: Guidelines for Developing Machine Learning ModelsSemantic proximity Read ↗

Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.Semantic proximity Read ↗

RNA-Sequencing Reveals Candidate Genes/Pathways Associated with Resistance to MDM2 Antagonist Idasanutlin in TP53 Wild-Type Chronic Lymphocytic LeukemiaSemantic proximity Read ↗

Deep learning-driven drug response prediction and mechanistic insights in cancer genomicsSemantic proximity Read ↗

Predicting clinical outcomes of cancer patients with a p53 deficiency gene signatureSemantic proximity Read ↗

Identification of predictors of drug sensitivity using patient-derived models of esophageal squamous cell carcinomaSemantic proximity Read ↗

PDXGEM: Patient-Derived Tumor Xenograft based Gene Expression Model for Predicting Clinical Response to Anticancer Therapy in Cancer PatientsSemantic proximity Read ↗

Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.